Name: Cognitive Function in Type 2 Diabetes Mellitus Patients: Combination Therapy of Oral Hypoglycemic Agents (en Inglés)
SKU: 63929510
Price: 1052.33 MXN
Availability: InStock
Author: Anand Vijayakumar Palur Ramakrishnan; Vidhya N.
ISBN: 9786208417833

portada Cognitive Function in Type 2 Diabetes Mellitus Patients: Combination Therapy of Oral Hypoglycemic Agents (en Inglés)

Cognitive Function in Type 2 Diabetes Mellitus Patients: Combination Therapy of Oral Hypoglycemic Agents (en Inglés)

Formato

Libro Físico

Editorial

Lap Lambert Academic Publishing

Autor

Anand Vijayakumar Palur Ramakrishnan; Vidhya N.

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

ISBN13

9786208417833

Cognitive Function in Type 2 Diabetes Mellitus Patients: Combination Therapy of Oral Hypoglycemic Agents (en Inglés)

Anand Vijayakumar Palur Ramakrishnan; Vidhya N. (Autor) · Lap Lambert Academic Publishing · Tapa Blanda

Libro Nuevo Importado

Envío: 22 a 27 días háb.

$ 1,753.88$ 1,052.33

-40%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 10 unidades

$ 1,052.33

¡Envío Gratis! Llega entre el 08 Oct y el 16 Oct a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Cognitive Function in Type 2 Diabetes Mellitus Patients: Combination Therapy of Oral Hypoglycemic Agents (en Inglés)"

Cognitive dysfunction in type 2 diabetes mellitus is associated with decrease in psychomotor speed, frontal lobe/executive function, verbal memory, processing speed, complex motor functioning, working memory, immediate recall. Although, type 2 diabetes is associated with several other vascular risk factors of dementia, diabetes itself has been implicated as an independent risk factor for cognitive impairment and dementia. The design was a prospective observation study to assess the cognitive function of diabetic patients treated with various classes of oral hypoglycemic with or without co-morbidities in various hospitals in Nilgiris and various tertiary health centers, Coimbatore. 400 patients were screened out of which 325 patients fulfilled the inclusion and exclusion criteria. The present study showed the patients taking dipeptidyl peptidase-4 inhibitors along with metformin showed a better global cognitive score than patients taking alpha glucosidase inhibitors, thiazolidinediones or sulphonylureas along with metformin.